Ankyra Therapeutics Unveils First-in-Class CD137-Anchored Immunotherapy ANK-203 with Promising Preclinical Anti-Tumor Activity
Key Insights
Ankyra Therapeutics (search) presented preclinical data on ANK-203 (search), a first-in-class anchored immunotherapy targeting CD137 (search) (4-1BB (search)) pathway at the AACR Immuno-Oncology Conference.
ANK-203 (search) demonstrated robust activation of the CD137 (search) immune pathway and regression of established tumors with no observed systemic toxicity in preclinical studies.
The therapy induced anti-tumor responses in both local and distant untreated tumors, suggesting systemic immune activation while maintaining localized delivery.
Ankyra Therapeutics (search) announced preclinical data on ANK-203 (search), a novel anchored immunotherapy targeting the CD137 (search) (4-1BB (search)) immune pathway, at the American Association of Cancer Research (AACR) Immuno-Oncology Conference in Los Angeles. The first-in-class therapy demonstrated strong anti-tumor activity with no observed systemic toxicity in preclinical studies, potentially addressing long-standing safety challenges that have limited CD137-based cancer treatments.
Novel Anchoring Platform Addresses CD137 Toxicity Challenges
ANK-203 (search) is designed to activate the CD137 (search) (4-1BB (search)) immune pathway through localized delivery and retention at the tumor site. In preclinical studies, the therapy demonstrated robust activation of the CD137 immune pathway and regression of established tumors following localized administration. Treatment was well tolerated, with no significant safety signals observed.
"CD137 (search) has long been recognized as a powerful immune costimulatory molecule with a high potential for cancer immunotherapy, but safety challenges have constrained its clinical potential," said Sailaja Battula, PhD, Chief Scientific Officer at Ankyra Therapeutics (search). "By anchoring CD137 locally, ANK-203 (search) enables focused immune activation where it matters most – at the tumor site – while minimizing systemic exposure, offering a differentiated approach to maximize clinical benefit."
Systemic Immune Response Despite Localized Delivery
Beyond local tumor control, ANK-203 (search) induced anti-tumor responses in distant, untreated tumors, suggesting the induction of a systemic immune response. This finding indicates that localized administration can generate broader therapeutic effects while maintaining the safety advantages of targeted delivery.
The data were presented in an oral session titled "Agonistic CD137 (search) (4-1BB (search)) anchored immunotherapy (ANK-203 (search)) elicits potent 4-1BBL signaling in vitro and therapeutic responses against established tumors without systemic toxicity in vivo" (abstract # 64034).
Platform Expansion Beyond Cytokines
ANK-203 (search) represents an expansion of Ankyra's anchored immunotherapy platform beyond cytokines to monoclonal antibodies. The company's pipeline also includes tolododekin alfa (search), an IL-12 (search) anchored immunotherapy with promising Phase 1 clinical activity and favorable tolerability as monotherapy in advanced solid tumors.
"Our anchored immunotherapy platform has already demonstrated promising clinical activity with tolododekin alfa (search), validating our approach to improving the therapeutic index of potent immune modulators, like IL-12 (search)," said Howard Kaufman, MD, Chief Executive Officer at Ankyra Therapeutics (search). "ANK-203 (search) extends our platform's application beyond cytokines to monoclonal antibodies and expands our pipeline, reinforcing its versatility and underscoring the potential to realize the promise of therapeutics that have been shelved due to toxicity."
Next Steps in Development
Based on these findings, Ankyra plans to advance ANK-203 (search) through additional preclinical studies to further characterize immune mechanisms and support potential clinical development. The company's anchoring platform is designed to allow higher doses for greater therapeutic impact while limiting systemic exposure, potentially unlocking the full therapeutic potential of immune-modulating drugs previously limited by toxicity concerns.